Lamivudine has been studied continuously since the mid-1990s. Most of the interesting recent research is not about whether it works but about how few other drugs it needs alongside it.
What established it?
Early combination trials in the mid-1990s, which demonstrated that lamivudine added to zidovudine produced substantially better outcomes than zidovudine alone. It was part of the shift to combination therapy that transformed HIV from a fatal to a manageable condition.
What does the long-term safety data show?
Remarkably little. Cohorts following people for two decades and more have not identified organ toxicity attributable to lamivudine. Unlike the older thymidine analogues, it does not cause significant mitochondrial damage, fat loss or neuropathy.
What did GEMINI establish?
That dolutegravir with lamivudine alone maintains viral suppression as effectively as a three-drug regimen in people starting treatment. This was a significant result, since it reduces cumulative drug exposure over a lifetime of treatment.
What did TANGO and SALSA show?
That people already suppressed on three-drug regimens could switch to dolutegravir with lamivudine and maintain suppression. Together with GEMINI, that established two-drug therapy as a mainstream option rather than an experiment.
Who is it not suitable for?
The trials excluded people with hepatitis B, since two-drug therapy would not cover it adequately, and those with very high starting viral loads or existing resistance. Those exclusions carry into practice.
What is known about M184V?
The single mutation conferring lamivudine resistance is one of the best characterised in HIV. It reduces the virus's replication capacity and increases susceptibility to zidovudine and tenofovir, which is an unusual combination of effects.
Why does that matter?
Because a virus carrying it is less fit. Some regimens retain lamivudine deliberately in people with the mutation, accepting the resistance in exchange for the fitness cost it imposes. That is a specialist strategy rather than routine practice.
How does it compare with emtricitabine?
Head-to-head comparisons have found essentially equivalent effectiveness, which is unsurprising given how similar they are. Guidelines treat them as interchangeable in most situations.
What about hepatitis B?
Lamivudine suppresses hepatitis B effectively at first and resistance develops over years of use at a substantial rate, considerably higher than with tenofovir. That is why tenofovir is preferred where hepatitis B needs treating.
What about pregnancy?
Extensive data, with one of the longest records of any antiretroviral. It is widely used during pregnancy and in newborns and is not associated with increased birth defects.
What about children?
Used from infancy with weight-based dosing and a long paediatric safety record. Pancreatitis has been reported rarely in children, which is monitored for.
What does real-world data show?
Consistent with the trials. Discontinuation attributed specifically to lamivudine is rare, and it appears in more regimens worldwide than almost any other antiretroviral.
What is still being studied?
Mainly further simplification strategies and its role alongside long-acting agents. Its own properties are thoroughly established.
Where can you read the evidence yourself?
NAM aidsmap summarises HIV research reliably, and the British HIV Association publishes the guidelines UK clinicians follow. Both are freely available and considerably more useful than a general search.
How should you read a headline about it?
Carefully. Reports about antiretrovirals often describe single studies, early findings or practice in other countries. Checking a claim against NAM aidsmap, or asking your clinic, is quicker than assessing the study design yourself.
Do guidelines change quickly?
Deliberately slowly. Recommendations shift when several studies point the same way rather than after one result. If something you read about lamivudine seems to contradict what you were told, ask before acting on it.
What has not been established?
Outcomes over several decades, in most cases, simply because the follow-up does not yet exist. That is a reason monitoring continues rather than a warning, and it applies to almost every modern antiretroviral.
Does the evidence apply to you?
Trials recruit particular populations and transfer best to people who resemble them. Where a study excluded a group, that is a gap rather than a negative finding, and it is fair to ask what your clinician's recommendation actually rests on.